Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPTSNASDAQ:DWTXNASDAQ:HCWBNASDAQ:HOTH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTSBiophytis$13.37$8.05▼$168.80$2.89M1.057,291 shs18,500 shsDWTXDogwood Therapeutics$5.27+1.7%$4.81$1.62▼$29.28$10.07M1.981.72 million shs26,278 shsHCWBHCW Biologics$7.21-6.7%$8.53$5.00▼$100.80$10.38M0.85261,021 shs24,943 shsHOTHHoth Therapeutics$0.93+12.0%$0.86$0.58▼$3.80$12.28M0.533.49 million shs297,464 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTSBiophytis0.00%0.00%0.00%0.00%0.00%DWTXDogwood Therapeutics0.00%+0.57%+4.98%+22.84%+526,999,900.00%HCWBHCW Biologics0.00%-5.62%+3.54%-48.03%-81.88%HOTHHoth Therapeutics0.00%-1.71%-5.65%-3.52%-28.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTSBiophytisN/AN/AN/AN/AN/AN/AN/AN/ADWTXDogwood Therapeutics1.7551 of 5 stars3.50.00.00.02.70.00.6HCWBHCW Biologics2.1365 of 5 stars3.52.00.00.01.63.30.0HOTHHoth Therapeutics2.7366 of 5 stars3.63.00.00.02.30.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTSBiophytis 0.00N/AN/AN/ADWTXDogwood Therapeutics 3.00Buy$10.0093.24% UpsideHCWBHCW Biologics 3.00Buy$35.00382.76% UpsideHOTHHoth Therapeutics 3.25Buy$4.00338.60% UpsideCurrent Analyst Ratings BreakdownLatest BPTS, HCWB, HOTH, and DWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025HCWBHCW BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $35.004/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.004/15/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/31/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/10/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/4/2025HOTHHoth TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTSBiophytisN/AN/AN/AN/A($17.29) per shareN/ADWTXDogwood TherapeuticsN/AN/AN/AN/A$4.94 per shareN/AHCWBHCW Biologics$1.45M7.22N/AN/A$0.37 per share19.59HOTHHoth TherapeuticsN/AN/AN/AN/A$2.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTSBiophytis-$18.43MN/A0.00N/AN/AN/AN/AN/AN/ADWTXDogwood Therapeutics-$5.30M-$18.04N/AN/AN/AN/A-217.12%-172.06%8/14/2025 (Estimated)HCWBHCW Biologics-$24.99M-$23.25N/A∞N/A-1,067.82%-2,516.84%-132.95%N/AHOTHHoth Therapeutics-$7.84M-$1.14N/AN/AN/AN/A-89.68%-82.61%8/8/2025 (Estimated)Latest BPTS, HCWB, HOTH, and DWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HCWBHCW BiologicsN/A-$0.05N/A-$0.05N/AN/A5/12/2025Q1 2025HOTHHoth Therapeutics-$0.34-$0.27+$0.07-$0.27N/AN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/A3/31/2025Q4 2024DWTXDogwood Therapeutics-$1.49-$6.29-$4.80-$6.29N/AN/A3/28/2025Q4 2024HCWBHCW BiologicsN/A-$3.20N/A-$0.08N/A$0.40 million3/27/2025Q4 2024HOTHHoth Therapeutics-$0.39-$0.32+$0.07-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTSBiophytisN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/AHOTHHoth TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTSBiophytisN/A0.720.72DWTXDogwood TherapeuticsN/A1.711.71HCWBHCW BiologicsN/A0.070.07HOTHHoth TherapeuticsN/A10.1710.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTSBiophytis0.05%DWTXDogwood Therapeutics9.05%HCWBHCW Biologics2.96%HOTHHoth Therapeutics7.08%Insider OwnershipCompanyInsider OwnershipBPTSBiophytis3.70%DWTXDogwood Therapeutics3.90%HCWBHCW Biologics49.90%HOTHHoth Therapeutics10.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPTSBiophytis22351,000338,000Not OptionableDWTXDogwood Therapeutics51.91 million1.17 millionN/AHCWBHCW Biologics401.44 million22.32 millionNot OptionableHOTHHoth Therapeutics413.21 million6.18 millionNot OptionableBPTS, HCWB, HOTH, and DWTX HeadlinesRecent News About These CompaniesWall Street Zen Upgrades Hoth Therapeutics (NASDAQ:HOTH) to HoldJune 1 at 3:47 AM | americanbankingnews.comHT-KIT Shows Activity in Rare KIT-Driven Cancers, Preclinical Data FindsMay 29, 2025 | curetoday.comHoth Therapeutics announces positive preclinical results for HT-KIT, a precision antisense therapy targeting rare and aggressive KIT-driven cancersMay 14, 2025 | pharmabiz.comHoth Therapeutics reports promising HT-KIT preclinical resultsMay 13, 2025 | investing.com/C O R R E C T I O N -- Hoth Therapeutics, Inc./May 12, 2025 | gurufocus.com/C O R R E C T I O N -- Hoth Therapeutics, Inc./ | HOTH Stock NewsMay 12, 2025 | gurufocus.comHoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven CancersMay 12, 2025 | prnewswire.comCutaneous Lupus Erythematosus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and CompaniesMay 6, 2025 | theglobeandmail.comHoth Therapeutics confirms patent application fee paymentMay 3, 2025 | investing.comTreatment With HT-KIT Shows Early Preclinical Activity in GIST ModelsApril 27, 2025 | curetoday.comHoth Therapeutics’ HT-001 shows efficacy in Phase 2a pruritus trialApril 17, 2025 | markets.businessinsider.comHoth Therapeutics granted Japanese patent for novel RNA-based cancer therapyApril 17, 2025 | markets.businessinsider.comHoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology PlatformApril 17, 2025 | prnewswire.comHoth Therapeutics reports interim data from Phase IIa trial of HT-001 for pruritusApril 17, 2025 | msn.comHoth Therapeutics, Inc.: Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical TrialApril 15, 2025 | finanznachrichten.deHoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical TrialApril 15, 2025 | prnewswire.comHoth Therapeutics announces collaboration with Washington UniversityApril 3, 2025 | markets.businessinsider.comHoth Therapeutics reports data from its Alzheimer’s candidate HT-ALZApril 2, 2025 | markets.businessinsider.comHoth Flat on Hookup with Washington Univ.April 2, 2025 | baystreet.caHoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZApril 2, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTS, HCWB, HOTH, and DWTX Company DescriptionsBiophytis NASDAQ:BPTSBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Dogwood Therapeutics NASDAQ:DWTX$5.27 +0.09 (+1.74%) Closing price 04:00 PM EasternExtended Trading$5.20 -0.07 (-1.35%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.HCW Biologics NASDAQ:HCWB$7.21 -0.52 (-6.73%) Closing price 04:00 PM EasternExtended Trading$7.60 +0.39 (+5.41%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Hoth Therapeutics NASDAQ:HOTH$0.93 +0.10 (+12.01%) Closing price 04:00 PM EasternExtended Trading$0.93 0.00 (0.00%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
